About 10% of Americans have Type 2 diabetes (T2), often along with obesity and heart disease.
Our European study explores Time in Range in diabetes, comparing outcomes and differences across six countries.
Our survey of 190 U.S. endocrinologists finds GLP-1 and SGLT2 prescribing at 90%+ and rising, while many patients resist starting basal insulin.
